Back
Pharmacological treatment of idiopathic pulmonary fibrosis: an update.
Journal article

Pharmacological treatment of idiopathic pulmonary fibrosis: an update.

  • Spagnolo P Medical University Clinic, Canton Hospital Baselland, Liestal, Switzerland; University of Basel, Basel, Switzerland. Electronic address: paolo.spagnolo@ksbl.ch.
  • Wells AU Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
  • Collard HR Division of Pulmonary, Critical Care Medicine, Sleep and Allergy, Department of Medicine, University of California, San Francisco, CA, USA.
  • 2015-01-24
Published in:
  • Drug discovery today. - 2015
Animals
Comorbidity
Disease Models, Animal
Disease Progression
Humans
Idiopathic Pulmonary Fibrosis
Indoles
Lung
Pyridones
Risk Factors
Time Factors
Treatment Outcome
English Idiopathic pulmonary fibrosis (IPF) is a progressive and almost invariably lethal disease that affects primarily older adults. After a decade of negative (or inconsistent) results, two recent clinical trials have demonstrated that slowing disease progression with medication is possible. An improved understanding of disease pathogenesis, epidemiology, and diagnostic criteria has been key to this success. Yet, this is only the beginning. It is hoped that continuous efforts by dedicated scientists and clinicians, patient organizations, health authorities, and pharmaceutical companies will soon lead to the development of more effective and better-tolerated treatment strategies for this devastating disease.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/53496
Statistics
Document views: 38 File downloads: